AUTHOR=Qin Zhongqiang , Xie Bo , Qian Jingyu , Ma Xiang , Zhang Lan , Wei Jianzhu , Wang Zhaoying , Fan Longfei , Zhu Ziyi , Qian Zhen , Yin Hongxiang , Zhu Fangquan , Tan Yulin 

TITLE=Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1144269

DOI=10.3389/fonc.2023.1144269

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Ribonucleotide reductase regulatory subunit M2 (RRM2) has been reported to be an oncogene in some malignant tumors, such as lung adenocarcinoma, oral squamous cell carcinoma, glioblastoma, and breast cancer. However, the clinical significance of RRM2 in hepatocellular carcinoma has been less studied. The aim of this study was to assess the importance of RRM2 in hepatocellular carcinoma (HCC) based on the Cancer Genome Atlas (TCGA) database.</p></sec><sec><title>Methods</title><p>The RRM2 expression levels and clinical features were downloaded from the TCGA database. Immunohistochemistry results between tumor tissues and normal tissues were downloaded from the Proteinatlas database. Meanwhile, the expression levels of RRM2 in tumor and paraneoplastic tissues were further verified by qRT-PCR and Western Blotting. Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein-interactions (PPI) network were constructed to analyze RRM2-related downstream molecules. In addition, RRM2 expression-related pathways performed by gene set enrichment analysis (GSEA). Association analysis of RRM2 gene expression and immune infiltration was performed by single-sample GSEA (ssGSEA).</p></sec><sec><title>Results</title><p>The RRM2 expression level in tumor tissues was higher than normal tissues (<italic>P &lt;</italic>0.001). The elevated expression of RRM2 in HCC was significantly correlated with T stage (<italic>P &lt;</italic>0.05), pathologic stage (<italic>P &lt;</italic>0.05), tumor status (<italic>P &lt;</italic>0.05), histologic grade (<italic>P&lt;</italic>0.001), and AFP (<italic>P &lt;</italic>0.001). HCC with higher RRM2 expression was positively associated with worse OS (overall survival), PFS (progression-free survival), and DSS (disease-specific survival). In the univariate analysis, the expression of RRM2, T stage, M stage, pathologic stage, and tumor status were negatively correlated with OS (<italic>P &lt;</italic>0.05). Further analysis using multivariate Cox regression showed that tumor status (<italic>P&lt;</italic>0.01) and RRM2 expression (<italic>P&lt;</italic>0.05) were independent prognostic factors of OS in HCC. GO/KEGG analysis showed that the critical biological process (chromosome condensation and p53 signaling pathway) might be the possible function mechanism in promoting HCC. Moreover, GSEA showed that several pathways were enriched in RRM2 high-expression samples, including PD-1 signaling, cell cycle, P27 pathway, and T cell receptor signaling pathway. RRM2 was significantly correlated with the infiltration level of CD8 T cells, Cytotoxic cells, DCs, Neutrophils, NK cells, and T helper cells (<italic>P &lt;</italic>0.05).</p></sec><sec><title>Conclusion</title><p>Over-expression of RRM2 predict adverse prognosis and is correlated with immune infiltrates in HCC. RRM2 may be a significant molecular biomarker for HCC diagnosis and prognosis.</p></sec>